392 related items for PubMed ID: 14631124
1. Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment.
Lus G, Romano F, Scuotto A, Accardo C, Cotrufo R.
Eur Neurol; 2004; 51(1):15-20. PubMed ID: 14631124
[Abstract] [Full Text] [Related]
2. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[Abstract] [Full Text] [Related]
3. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M, Horakova D.
Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
[Abstract] [Full Text] [Related]
4. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.
Fernández O, Guerrero M, Mayorga C, Muñoz L, Leán A, Luque G, Hervás M, Fernández V, Capdevila A, de Ramón E.
J Neurol; 2002 Aug; 249(8):1058-62. PubMed ID: 12195454
[Abstract] [Full Text] [Related]
5. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[Abstract] [Full Text] [Related]
6. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
[Abstract] [Full Text] [Related]
7. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.
Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V.
Mult Scler; 2010 Apr 26; 16(4):450-4. PubMed ID: 20150398
[Abstract] [Full Text] [Related]
8. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.
De Stefano N, Sormani MP, Stubinski B, Blevins G, Drulovic JS, Issard D, Shotekov P, Gasperini C.
J Neurol Sci; 2012 Jan 15; 312(1-2):97-101. PubMed ID: 21880336
[Abstract] [Full Text] [Related]
9. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
Pokryszko-Dragan A, Bilińska M, Gruszka E, Dubik-Jezierzańska M.
Pol Merkur Lekarski; 2005 Nov 15; 19(113):654-8. PubMed ID: 16498805
[Abstract] [Full Text] [Related]
10. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M, ACT Investigators.
Neurology; 2009 Feb 10; 72(6):535-41. PubMed ID: 19204263
[Abstract] [Full Text] [Related]
11. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA.
Lancet Neurol; 2011 Apr 10; 10(4):338-48. PubMed ID: 21397567
[Abstract] [Full Text] [Related]
12. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X.
Mult Scler; 2008 May 10; 14(4):479-84. PubMed ID: 18562504
[Abstract] [Full Text] [Related]
13. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators.
N Engl J Med; 2006 Mar 02; 354(9):911-23. PubMed ID: 16510745
[Abstract] [Full Text] [Related]
14. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Ravnborg M, Sørensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, Bartholomé E, Constantinescu CS, Beer K, Garde E, Sperling B.
Lancet Neurol; 2010 Jul 02; 9(7):672-80. PubMed ID: 20542736
[Abstract] [Full Text] [Related]
15. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.
Cohen BA, Rivera VM.
Curr Med Res Opin; 2010 Apr 02; 26(4):827-38. PubMed ID: 20121658
[Abstract] [Full Text] [Related]
16. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V.
Neurol Sci; 2005 Dec 02; 26 Suppl 4():S174-8. PubMed ID: 16388353
[Abstract] [Full Text] [Related]
17. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.
Sormani MP, Li DK, Bruzzi P, Stubinski B, Cornelisse P, Rocak S, De Stefano N.
Neurology; 2011 Nov 01; 77(18):1684-90. PubMed ID: 21975200
[Abstract] [Full Text] [Related]
18. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
Meca-Lallana JE, de Mingo-Casado P, Amorin-Díaz M, Martínez-Navarro ML, Barreiro AF.
Clin Ther; 2010 Jun 01; 32(6):1061-6. PubMed ID: 20637960
[Abstract] [Full Text] [Related]
19. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
Clin Ther; 2008 Jun 01; 30(6):1102-12. PubMed ID: 18640466
[Abstract] [Full Text] [Related]
20. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.
Reggio E, Nicoletti A, Fiorilla T, Politi G, Reggio A, Patti F.
J Neurol; 2005 Oct 01; 252(10):1255-61. PubMed ID: 15940386
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
